Yoon Hyeon-Jeong, Moon Ja Young, Kim Hyun Jee, Park Sodam, Choi Ji Suk, Choi Hoon-In, Kim Seoyoung, Yoon Kyung Chul
Department of Ophthalmology, Chonnam National University Medical School and Hospital, Gwangju 61469, Republic of Korea.
Safety and Microbiology Lab, Amorepacific R&I Center, Yongin-si 17074, Republic of Korea.
J Clin Med. 2024 Dec 29;14(1):138. doi: 10.3390/jcm14010138.
Sensitivity to ocular irritation varies among individuals, being influenced by clinical, subjective, and biochemical factors. This study aimed to evaluate individual variability in ocular irritation sensitivity, focusing on clinical parameters, pain perception, and tear neuromediator profiles. Sixty female participants aged 20-40 were classified into high-sensitivity and low-sensitivity groups based on their response to an irritant (Tween20). Clinical assessments included the ocular surface disease index (OSDI), tear break-up time (TBUT), Schirmer test, and corneal touch threshold measured with the Cochet-Bonnet esthesiometer. Pain sensitivity was assessed using the pain sensitivity questionnaire (PSQ), and tear neuromediators were quantified in tear samples before and after stimulation. The concentrations of calcitonin gene-related peptide (CGRP), nerve growth factor, neuropeptide Y, vasoactive intestinal peptide (VIP), and substance P were measured using an enzyme-linked immune sorbent assay (ELISA). The high-sensitivity group exhibited significantly higher OSDI scores ( = 0.038). No significant differences were observed in TBUT, corneal staining scores, or Schirmer's test results. The PSQ results revealed that the high-sensitivity group had lower total and moderate pain scores ( = 0.037 and = 0.040, respectively). An analysis of the tear neuromediator showed elevated baseline CGRP levels ( = 0.017) and a significant post-stimulation increase in substance P ( = 0.021) in the high-sensitivity group. These findings emphasize the value of combining clinical, subjective, and biochemical measures to understand sensitivity to ocular irritation. This comprehensive approach may guide the development of safer cosmetic formulations and improve safety assessment protocols.
个体对眼部刺激的敏感性各不相同,受到临床、主观和生化因素的影响。本研究旨在评估眼部刺激敏感性的个体差异,重点关注临床参数、疼痛感知和泪液神经介质谱。60名年龄在20至40岁之间的女性参与者根据其对刺激物(吐温20)的反应被分为高敏组和低敏组。临床评估包括眼表疾病指数(OSDI)、泪膜破裂时间(TBUT)、Schirmer试验以及使用Cochet-Bonnet眼压计测量的角膜触觉阈值。使用疼痛敏感性问卷(PSQ)评估疼痛敏感性,并在刺激前后对泪液样本中的泪液神经介质进行定量。使用酶联免疫吸附测定(ELISA)测量降钙素基因相关肽(CGRP)、神经生长因子、神经肽Y、血管活性肠肽(VIP)和P物质的浓度。高敏组的OSDI评分显著更高( = 0.038)。在TBUT、角膜染色评分或Schirmer试验结果中未观察到显著差异。PSQ结果显示,高敏组的总疼痛评分和中度疼痛评分较低(分别为 = 0.037和 = 0.040)。对泪液神经介质的分析表明,高敏组的基线CGRP水平升高( = 0.017),刺激后P物质显著增加( = 0.021)。这些发现强调了结合临床、主观和生化测量来理解眼部刺激敏感性的价值。这种综合方法可能会指导更安全的化妆品配方的开发,并改进安全性评估方案。